How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,087 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Depo-Provera

Depo-Provera Medroxyprogesterone acetate - Wikipedia Medroxyprogesterone acetate From Wikipedia, the free encyclopedia (Redirected from ) Not to be confused with , a natural and bioidentical progestogen. Medroxyprogesterone acetate Clinical data Pronunciation Provera, Depo-Provera, Depo-SubQ Provera 104, Curretab, Cycrin, Farlutal, Gestapuran, Perlutex, Veramix, others Synonyms MPA; DMPA; Methylhydroxy progesterone acetate; Methylacetoxy progesterone; MAP; Methypregnone; Metipregnone; 6α-Methyl (...) 34 O 4 386.532 g/mol g·mol −1 3D model ( ) C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C InChI=InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1 Key:PSGAAPLEWMOORI-PEINSRQWSA-N Medroxyprogesterone acetate ( MPA ), also known as depot medroxyprogesterone acetate ( DMPA ) and sold under the brand name Depo-Provera among others, is a of the type

2012 Wikipedia

22. What is the latest time that depo medroxyprogestogen acetate can be given? It is usually 12 weeks + 5 days. I believe there is some evidence that it can be given at 14 weeks after last depo and even i

to use additional contraception or avoid sex for the next 7 days. The need for emergency contraception should be assessed individually.” In December 2009 TRIP Answers answered a similar question as to whether the duration of repeat depo provera had been extended to thirteen and a half weeks (2). We have provided a link to the answer below. 1. 2. Answered 28 April 2010 Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK. (...) What is the latest time that depo medroxyprogestogen acetate can be given? It is usually 12 weeks + 5 days. I believe there is some evidence that it can be given at 14 weeks after last depo and even i What is the latest time that depo medroxyprogestogen acetate can be given? It is usually 12 weeks + 5 days. I believe there is some evidence that it can be given at 14 weeks after last depo and even if unprotected SI has occurred emergency contraception is not indicated. - Trip Database or use

2010 TRIP Answers

23. Is it correct that the duration for repeat depo provera is now thirteen and a half weeks?

Is it correct that the duration for repeat depo provera is now thirteen and a half weeks? Is it correct that the duration for repeat depo provera is now thirteen and a half weeks? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine (...) content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is it correct that the duration for repeat depo provera is now thirteen and a half weeks? The SPC for depo-provera [1] states: "Further doses: These should be given at 12 week intervals, however, as long

2009 TRIP Answers

24. What is the risk of osteoporosis in someone on long term depo-provera?

What is the risk of osteoporosis in someone on long term depo-provera? What is the risk of osteoporosis in someone on long term depo-provera? - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers (...) , patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com What is the risk of osteoporosis in someone on long term depo-provera? In 2008 the Faculty of Sexual and Reproductive Healthcare published an answer to the question “What is the most recent advice concerning bone mineral density and the use of depot

2009 TRIP Answers

25. Is there any evidence that you must give depo provera in to the gluteus muscle, and that it is ineffectual/ dangerous/ any thing else if given into deltoid?

Is there any evidence that you must give depo provera in to the gluteus muscle, and that it is ineffectual/ dangerous/ any thing else if given into deltoid? Is there any evidence that you must give depo provera in to the gluteus muscle, and that it is ineffectual/ dangerous/ any thing else if given into deltoid? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document (...) ’ and this is something we aim to deliver for every single search. As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence that you must give depo provera in to the gluteus muscle

2009 TRIP Answers

26. Is there any evidence that Depo-Provera is unreliable in a very obese woman, and any for giving a double dose to those with high BMI?

Is there any evidence that Depo-Provera is unreliable in a very obese woman, and any for giving a double dose to those with high BMI? Is there any evidence that Depo-Provera is unreliable in a very obese woman, and any for giving a double dose to those with high BMI? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document (...) . As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence that Depo-Provera is unreliable in a very obese woman, and any for giving a double dose to those with high BMI? We

2009 TRIP Answers

27. What evidence is there to support that Depo Provera can prevent endometrial cancer?

What evidence is there to support that Depo Provera can prevent endometrial cancer? What evidence is there to support that Depo Provera can prevent endometrial cancer? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing (...) including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com What evidence is there to support that Depo Provera can prevent endometrial cancer? John Guillebaud’s book Contraception: Your questions answered (Fourth Edition, 2004) has a question, what are the latest data about DMPA and cancer

2009 TRIP Answers

28. Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial. (Abstract)

Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial. Irregular bleeding is often cited as the reason for discontinuation of depot-medroxyprogesterone acetate (DMPA) after the first injection. Estrogen supplementation during DMPA initiation may decrease bleeding and improve continuation.This prospective, randomized, controlled trial evaluated estrogen supplementation during DMPA initiation. Women initiating DMPA were randomized to receive an estradiol

2010 Contraception Controlled trial quality: predicted high

29. Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: SGO and ASRM Evidence-Based Review

-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2016;2:1434–40. 22. WeissNS,SayvetzTA.Incidenceofendometrialcancerinrelationtotheuse of oral contraceptives. N Engl J Med 1980;302:551–4. 23. LuKH,LooseDS,YatesMS,Nogueras-GonzalezGM,MunsellMF,ChenLM, Lynch H, Cornelison T, Boyd-Rogers S, Rubin M, Daniels MS, Conrad P, Milbourne A, Gershenson DM, Broaddus RR. Prospective, multi-center randomized intermediate biomarker study of Oral contraceptive vs. Depo-Provera for prevention (...) . Chemoprevention. Oral contraceptives have been shown to decrease the risk of endometrial cancer by 50% in thegeneralpopulation(22).Ithasbeenshownthattheendome- trium of women with Lynch Syndrome that are exposed to Depo-MedroxyprogesteroneorOCPsforthreemonthsshowde- creasedepithelialproliferationandinactive/secretoryhistology, suggestingthattheseagentsmaybeusefulforchemoprevention ofuterineandpossibly,ovariancancer.However,whetherthese effects result in an actual reduction in the risk of endometrial cancer

2020 Society for Assisted Reproductive Technology

33. Hormonal Contraceptives

2: Non-oral contraceptives for pharmacist prescribing Brand Name Components (EE – Ethinyl estradiol) Progestin Only Depo-Provera® Depo-Medroxyprogesterone Acetate 150mg IM Combination Nuvaring® EE 15mcg and etonogestrel 120mcg released daily Evra® EE 35mcg and norelgestromin 200mcg released daily Fee pseudoDIN 00951104; maximum of 1 claim per year Prescribe 1 or 2 months of therapy initially (3 months if using Seasonale, Seasonique or Depo-Provera). Can provide refills up to one year (...) are not associated with an increased risk of thromboembolism. 1) Non-prescription contraceptive options Failure rates with typical use over a year Male condoms (11-16%) Diaphragm (15%) Sponge (16-30%) Female condoms (20%) Spermicide alone (30%) Condoms provide protection against STIs 2) Prescription options Patients should be counselled about the advantages and disadvantages of long-acting reversible contraceptives (copper IUD, levonorgestrel-eluting IUDs, depo-medroxyprogresterone injection). If a long-acting

2018 medSask

36. Appropriate Use Criteria: Quantitative CT (QCT) Bone Mineral Densitometry

? Radiographic evidence of osteopenia ? Rheumatoid arthritis ? Thyroid disease ? Anyone on a medication associated with development of osteoporosis, including but not limited to the following medications: ? Glucocorticoids (e.g., prednisone, prednisolone, decadron, dexamethasone) – treatment for longer than 3 months ? Phenytoin (Dilantin) – treatment for longer than 3 months ? Heparin – treatment for longer than 1 month ? Depo-Provera injectable contraceptive – long-standing use (longer than 2 years

2018 AIM Specialty Health

37. Selected practice recommendations for contraceptive use

57 Combined pill and progestin-only pill 9 0.3 67 Evra patch 9 0.3 67 NuvaRing® 9 0.3 67 Depo-Provera 6 0.2 56 Intrauterine contraceptives ParaGard® (copper T) 0.8 0.6 78 Mirena® (levonorgestrel) 0.2 0.2 80 Implanon® 0.05 0.05 84 Female sterilization 0.5 0.5 100 Male sterilization 0.15 0.10 100 Emergency contraceptives: Emergency contraceptive pills or insertion of a copper intrauterine contraceptive after unprotected intercourse substantially reduces the risk of pregnancy. i Lactational (...) ; estimates for fertility awareness-based methods, withdrawal, the male condom, the pill and Depo-Provera are taken from the 1995 and 2002 National Survey of Family Growth corrected for underreporting of abortion. b Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. c Among couples attempting

2017 World Health Organisation Guidelines

38. PK of Depo SubQ Injected in the Upper Arm

Description Go to Brief Summary: A single-arm trial to demonstrate that Depo-SubQ Provera injected in the upper arm is adequate for effective contraception Condition or disease Intervention/treatment Phase Contraception Drug: Medroxyprogesterone acetate Not Applicable Detailed Description: A single-arm trial to demonstrate that the blood levels of medroxyprogesterone acetate are adequate for effective contraception when Depo-SubQ Provera 104 is injected in the upper arm Study Design Go to Layout table (...) and Interventions Go to Arm Intervention/treatment Experimental: Medroxyprogesterone acetate Single injection of Medroxyprogesterone acetate (hormonal contraceptive) Drug: Medroxyprogesterone acetate Injectable hormonal contraceptive Other Name: Depo-SubQ Provera 104 Outcome Measures Go to Primary Outcome Measures : Cmax (Maximal Serum Concentration of Medroxyprogesterone Acetate (MPA)) [ Time Frame: 120 days following injection ] Tmax (Time to Cmax) [ Time Frame: 120 days following injection ] AUC 0-91 (Area

2010 Clinical Trials

39. Randomized Control Trial Copper Intrauterine Device and Depo-medroxyprogesterone Acetate (DMPA) of HIV+ Women in Malawi

Completion Date : December 2011 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Depo Medroxyprogesterone Acetate Drug: Depo Medroxyprogesterone acetate DMPA 150 mg IM q 3 months Other Names: DMPA Depo Provera Active Comparator: Copper IUD (CuT360) Drug: Copper IUD Copper IUD (CuT360) Outcome Measures Go to Primary Outcome Measures : Adherence [ Time Frame: 1 year ] Number of clients (...) Randomized Control Trial Copper Intrauterine Device and Depo-medroxyprogesterone Acetate (DMPA) of HIV+ Women in Malawi Randomized Control Trial Copper Intrauterine Device and Depo-medroxyprogesterone Acetate (DMPA) of HIV+ Women in Malawi - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2010 Clinical Trials

40. Long-acting reversible contraception: subcutaneous depot medroxyprogesterone acetate (DMPA-SC)

2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary A new formulation of depot medroxyprogesterone acetate (DMPA) for subcutaneous administration (DMPA-SC 104 mg/0.65 ml, Sayana Press) was shown to be as effective as DMPA given by intramuscular administration (DMPA-IM 150 mg/ml, Depo-Provera) for preventing pregnancy. Bone mineral density (BMD) loss and weight gain were similar with both methods (...) of DMPA for subcutaneous administration (DMPA–SC) for use as long-term female contraception, administered every 13 weeks. It is an alternative to DMPA administered by intramuscular injection (DMPA-IM, Depo-Provera) and was launched in the UK in June 2013. DMPA works by inhibiting gonadotrophin secretion, which, in turn, prevents ovulation. This evidence summary is based on 3 trials that evaluated the contraceptive efficacy and safety of DMPA-SC. One of these was a randomised controlled trial

2014 National Institute for Health and Clinical Excellence - Advice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>